血压与脑淀粉样蛋白及tau蛋白病理关联的效应修饰因素
该研究基于美国国家阿尔茨海默病协调中心2005年至2022年6月的尸检神经病理数据,纳入2094名参与者,分析收缩压与脑淀粉样蛋白及tau蛋白负荷的关联是否受APOE ε4携带、年龄、脑血管负担和认知状态修饰。结果显示,在痴呆患者和有卒中史者中,收缩压与淀粉样蛋白及tau负荷的关联更显著;作者认为这些异质性关联模式需在活体AD病理评估的纵向研究中确认。
要点
- 在有卒中史者中,收缩压每升高10毫米汞柱与淀粉样蛋白负荷的OR为1.58,无卒中史者为1.14。
- 在痴呆患者中,收缩压每升高10毫米汞柱与tau负荷的OR为1.24,认知正常者为0.98。
- 卒中史和认知状态可能修饰收缩压与脑淀粉样蛋白及tau负荷的关联。
核心结论
- 既存脑血管负担和认知状态可能与收缩压升高交互,影响其与更高脑淀粉样蛋白及tau负荷的关联,有助于识别血压管理和AD预防的高危亚组。
- 这些异质性关联模式需在活体AD病理评估的纵向研究中确认。
研究设计与样本
- 基于美国国家阿尔茨海默病协调中心2005年至2022年6月期间有尸检神经病理测量数据的参与者进行分析。
- 主要暴露为前3次年度访视的平均收缩压,次要暴露为基线高血压状态。
- 脑AD病理采用Thal和Braak分期评估。
- 潜在修饰因素包括APOE ε4携带、年龄、卒中史和认知状态。
- 采用带交互项的多项逻辑回归检验效应修饰,并校正年龄、性别、APOE ε4携带、教育、降压药使用和距死亡年数。
主要发现
- 共纳入2094名参与者,基线年龄75±9.5岁,女性占51.4%。
- 收缩压较高与淀粉样蛋白及tau负荷较高的关联随卒中史和认知状态而变化,年龄或APOE ε4携带的效应修饰较不一致。
- 在痴呆患者(较无痴呆者)和有卒中史者(较无卒中史者)中,收缩压与淀粉样蛋白及tau负荷较高的关联更显著(所有交互作用P<0.05)。
关键数值与推荐
- 在卒中 vs 非卒中亚组中,收缩压每升高10毫米汞柱与淀粉样蛋白负荷的OR分别为1.58(95%CI 1.04-2.41) vs 1.14(95%CI 1.03-1.27)。
- 在卒中 vs 非卒中亚组中,收缩压每升高10毫米汞柱与tau负荷的OR分别为1.54(95%CI 1.00-2.36) vs 1.04(95%CI 0.96-1.12)。
- 在痴呆 vs 认知正常亚组中,收缩压每升高10毫米汞柱与淀粉样蛋白负荷的OR分别为1.39(95%CI 1.17-1.64) vs 1.12(95%CI 0.96-1.31)。
- 在痴呆 vs 认知正常亚组中,收缩压每升高10毫米汞柱与tau负荷的OR分别为1.24(95%CI 1.08-1.42) vs 0.98(95%CI 0.85-1.14)。
- 基线高血压状态也观察到类似结果。
临床怎么用
- 作者认为,既存脑血管负担和认知状态与收缩压升高的交互关联可能有助于识别血压管理和AD预防的高危亚组。
- 作者指出这些异质性关联模式需在活体AD病理评估的纵向研究中确认。
局限性
- 这些异质性关联模式需在活体AD病理评估的纵向研究中确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Hypertension is an important modifiable risk factor of Alzheimer disease (AD), but previous studies reported heterogeneous associations of late-life blood pressure (BP) with brain amyloid and tau pathologies. We investigated how the associations of BP with brain amyloid and tau vary by APOE ε4 carriership, age, cerebrovascular burden, and cognitive status. METHODS: We performed analyses among participants with postmortem neuropathology measurements (2005-June 2022) from the National Alzheimer's Coordinating Center. The average systolic BP (SBP) of the first 3 annual visits was the primary exposure, and baseline hypertension status was the secondary exposure. Brain AD pathologies were assessed using Thal and Braak staging. Potential modifiers included APOE ε4 carriership, age, stroke history, and cognitive status. Multinomial logistic regressions with interaction terms were used to test effect modification, adjusting for age, sex, APOE ε4 carriership, education, antihypertensive medication use, and years to death. RESULTS: Among 2,094 participants (baseline age: 75 ± 9.5 years; 51.4% women), the association of higher SBP with higher amyloid and tau burdens varied by stroke history and cognitive status while the effect modification by age or APOE ε4 carriership was less consistent. More pronounced associations of SBP with higher amyloid and tau burdens were observed in those with dementia (vs without dementia) and those with a history of stroke (vs without stroke) (All p interaction<0.05). The odds ratios (ORs) per 10-mm Hg increase in SBP in the stroke vs nonstroke subgroup were 1.58 (95% CI 1.04-2.41) vs 1.14 (1.03-1.27) for amyloid and 1.54 (1.00-2.36) vs 1.04 (0.96-1.12) for tau. When comparing dementia with cognitively normal subgroups, ORs were 1.39 (1.17-1.64) vs 1.12 (0.96-1.31) for amyloid and 1.24 (1.08-1.42) vs 0.98 (0.85-1.14) for tau. Similar findings were observed for baseline hypertension status. DISCUSSION: Preexisting cerebrovascular burden and cognitive status might interact with elevated SBP in their association with higher brain amyloid and tau, which could help identify high-risk subgroups for BP management and AD prevention. These heterogeneous association patterns need to be confirmed in longitudinal studies with in vivo AD pathology assessments.
引用
- Cai W, Neitzel J, Glodzik L, et al. Effect Modifiers of the Association of Blood Pressure With Brain Amyloid and Tau Pathology. Neurology. 2025. PMID: 40014836. doi:10.1212/WNL.0000000000213441
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。